Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer

The globo-series glycosphingolipids (GSLs) SSEA3, SSEA4, and Globo-H specifically expressed on cancer cells are found to correlate with tumor progression and metastasis, but the functional roles of these GSLs and the key enzyme β1,3-galactosyltransferase V (β3GalT5) that converts Gb4 to SSEA3 remain...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 116; no. 9; pp. 3518 - 3523
Main Authors Chuang, Po-Kai, Hsiao, Michael, Hsu, Tsui-Ling, Chang, Chuan-Fa, Wu, Chung-Yi, Chen, Bo-Rui, Huang, Han-Wen, Liao, Kuo-Shiang, Chen, Chen-Chun, Chen, Chi-Long, Yang, Shun-Min, Kuo, Chiung Wen, Chen, Peilin, Chiu, Ping-Tzu, Chen, I-Ju, Lai, Jiann-Shiun, Yu, Cheng-Der Tony, Wong, Chi-Huey
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 26.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The globo-series glycosphingolipids (GSLs) SSEA3, SSEA4, and Globo-H specifically expressed on cancer cells are found to correlate with tumor progression and metastasis, but the functional roles of these GSLs and the key enzyme β1,3-galactosyltransferase V (β3GalT5) that converts Gb4 to SSEA3 remain largely unclear. Here we show that the expression of β3GalT5 significantly correlates with tumor progression and poor survival in patients, and the globoseries GSLs in breast cancer cells form a complex in membrane lipid raft with caveolin-1 (CAV1) and focal adhesion kinase (FAK) which then interact with AKT and receptor-interacting protein kinase (RIP), respectively. Knockdown of β3GalT5 disrupts the complex and induces apoptosis through dissociation of RIP from the complex to interact with the Fas death domain (FADD) and trigger the Fas-dependent pathway. This finding provides a link between SSEA3/SSEA4/Globo-H and the FAK/CAV1/AKT/RIP complex in tumor progression and apoptosis and suggests a direction for the treatment of breast cancer, as demonstrated by the combined use of antibodies against Globo-H and SSEA4.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Contributed by Chi-Huey Wong, December 31, 2018 (sent for review October 2, 2018; reviewed by Yasuhiro Kajihara, Todd L. Lowary, and Peng George Wang)
Reviewers: Y.K., Osaka University; T.L.L., University of Alberta; and P.G.W., Georgia State University.
Author contributions: P.-K.C., M.H., T.-L.H., C.-F.C., and C.-H.W. designed research; P.-K.C., B.-R.C., H.-W.H., K.-S.L., C.-C.C., S.-M.Y., C.W.K., P.C., P.-T.C., and I.-J.C. performed research; M.H., C.-Y.W., C.-L.C., S.-M.Y., C.W.K., and P.C. contributed new reagents/analytic tools; P.-K.C., M.H., T.-L.H., J.-S.L., C.-D.T.Y., and C.-H.W. analyzed data; and P.-K.C., T.-L.H., K.-S.L., and C.-H.W. wrote the paper.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1816946116